Price target
3.010.000.00%
The 3 analysts offering 1 year price forecasts for 6C1 have a max estimate of — and a min estimate of —.
Analyst rating
Based on 5 analysts giving stock ratings to 6C1 in the past 3 months.
EPS
Reported
Estimate
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
6C1 EPS for the last quarter is 0.20 CHF despite the estimation of −0.18 CHF. In the next quarter EPS is expected to reach 0.11 CHF. Track more of CYTOMX THERAPEUTIC financials and stay on top of what is up with the company.
In the next quarter CYTOMX THERAPEUTIC revenue is expected to reach 31.44 M CHF. Check out CYTOMX THERAPEUTIC revenue and earnings and make informed decisions.
According to analysts, 6C1 price target is 3.01 CHF with a max estimate of 4.11 CHF and a min estimate of 2.05 CHF. Check if this forecast comes true in a year, meanwhile watch CYTOMX THERAPEUTIC stock price chart and keep track of the current situation with 6C1 news and stock market news.
We've gathered opinions of 5 analysts rating 6C1 stock in the past 3 months. After counting all points of view, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.